FDA Grants 2 Fast Track Designations to TT125-802 in EGFR/KRAS G12C NSCLC
Written by
Cancer Network
Published
0
comments
0
min
TT125-802 monotherapy shrank the tumors in 5 of 7 patients with drug-resistant NSCLC, and no thrombocytopenia was observed.